Clinical Research Details

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Study Description

This study will test the following experimental drugs: an injectable named semaglutide (SEMA) and a fixed-dose combination tablet named cilofexor/firsocostat (CILO/FIR) for the treatment of nonalcoholic steatohepatitis (NASH). NASH is a more severe form of nonalcoholic fatty liver disease in which the liver becomes fatty and inflamed and liver cells become injured. Scarring of the liver (fibrosis) may also occur. Fixed-dose combination means that two experimental drugs are in one tablet and the amount of each drug does not change.

Inclusion/Exclusion Criteria

Men and nonpregnant, nonlactating women between 18 and 80 years of age, inclusive, with compensated cirrhosis due to NASH, as determined by liver biopsy.

Investigators